Latest news & insights
Boyds shortlisted as an OBN Award finalist
Boyds has been shortlisted as a finalist in the Best Sector Support Organisation category at the 2018 OBN Awards. CEO and Founder, Professor Alan Boyd commented:
Boyds appoints Consultant Pharmaceutical Physician
Boyds is delighted to welcome Christine Smith as a Consultant Pharmaceutical Physician to support the clinical activities of the company and in particular supporting the
Clarification on the assessment of ATMPs
Boyds has welcomed the very timely final Regulation (EU) 2018/781 from the European Commission which describes the criteria to be used in the assessment of
Boyds recognised with prestigious Queen’s Award for Enterprise
Boyds has today been recognised with one of the UK’s most prestigious business awards – The Queen’s Award for Enterprise, International Trade for Outstanding Short
AMO Pharma announces results of Phase 2 proof-of-concept study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1 – Patients showed significant improvements
Health & Social Care Select Committee’s report on medicines, devices and substances of human origin has now been published
Back in December, Professor Alan Boyd was invited to appear before the Health & Social Care Select Committee in his capacity as President of the
Evaluation of advanced therapy medicines
The European Medicines Agency (EMA) has updated its procedural advice on the evaluation of advanced therapy medicinal products (ATMPs). The update aims to streamline some
Boyds acquires new Cambridge office to support rapid growth
Boyds is delighted to announce the opening of its new Cambridge office, which has involved an investment in excess of £0.5m in the purchase and
